title: An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition.
abstract: Targeting the epithelial-to-mesenchymal transition (EMT) is emerging as a novel intervention against tumor progression and metastatic dissemination, as well as the resistance to chemo- and radiotherapy displayed by multiple carcinomas. We have recently developed an immunotherapeutic approach to target a major driver of EMT, the T-box transcription factor T (also known as brachyury). This therapeutic paradigm is currently being tested in patients with advanced carcinomas in the context of a Phase I clinical trial.
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Claudia
authors.initials: C
authors.lastname: Palena
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Romaine I
authors.initials: RI
authors.lastname: Fernando
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Duane H
authors.initials: DH
authors.lastname: Hamilton
keywords: EMT; anticancer vaccines; brachyury; metastasis; therapeutic resistance